Biblio

Author [ Title(Asc)] Type Year
Filters: Author is Ljungman, Per  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis - the incidence remains high. Biol Blood Marrow Transplant. 2014.
S
Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, et al. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.
R
Cordonnier C, Maschmeyer G, Cesaro S, Ljungman P. Reporting infectious complications in haematology clinical trials should be improved. Clin Microbiol Infect. 2019.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
P
Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016.
M
Brands-Nijenhuis AVM, Labopin M, Schouten HC, Volin L, Socié G, Cornelissen JJ, Huynh A, Ljungman P, Malard F, Esteve J, et al. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission. A retrospective survey on behalf of the ALWP of EBMT. Haematologica. 2015.
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JHenri, et al. Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu. Am J Hematol. 2018.
Dalianis T, Eriksson B-M, Felldin M, Friman V, Hammarin A-L, Herthelius M, Ljungman P, Mölne J, Wennberg L, Swartling L. Management of BK-virus infection - Swedish recommendations. Infect Dis (Lond). 2019:1-6.
L
Cesaro S, Pillon M, Sauer M, Smiers F, Faraci M, de Heredia CDíaz, Wynn R, Greil J, Locatelli F, Veys P, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Tra. Bone Marrow Transplant. 2020.
I
Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, Ljungman P, Wagner AKathleen, Alici E. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One. 2019;14(2):e0211927.
Cesaro S, Tridello G, Knelange NSimone, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, et al. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. Bone Marrow Transplant. 2021.
Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, Lange J, Cuapio A, Blennow O, Hansson L, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022.
H
Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Andersson P-O, et al. High graft-versus-host disease-free, relapse/rejection-free survival and similar outcome of related and unrelated allogeneic stem cell transplantation for aplastic anemia - a nationwide Swedish cohort study. Biol Blood Marrow Transplant. 2019.
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
F
Raj K, Eikema D-J, McLornan DP, Olavarria E, Blok H-J, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, et al. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
E
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018.
D
Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, Styczyński J, Ward KN, Cesaro S. Donor CMV status influences the outcome of allogeneic stem cell transplantation; a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2018.
C
Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2015.
B
Vaht K, Brenner J, Ednersson SBram, Ljungman P, Brune M, Andersson P-O. Bone marrow expression of CD68/CD163 macrophages, IL-17, and FOXP3 cells in aplastic anaemia and their relation to prognosis. Eur J Haematol. 2022.
A
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Wedge E, Hansen JWerner, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MSkov, Nilsson L, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021.
Maeurer M, Magalhaes I, Andersson J, Ljungman P, Sandholm E, Uhlin M, Mattsson J, Ringdén O. Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. Transplantation. 2014;98(12):e95-e96.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, et al. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022.
Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner A-S, Neubauer A, Mielke S, Ljungman P, et al. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. Ann Hematol. 2021.